News
Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...
First, let's back up a bit and take a look at the Moderna story, from the glory days of a few years ago to its troubles today ...
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results